Evidence map›Paper›PMID 38307886›Full record

ArticleScientific reports2024

Association of vaccine status, reinfections, and risk factors with Long COVID syndrome.

Maria Elena Romero-Ibarguengoitia, Juan Francisco Rodríguez-Torres, Arnulfo Garza-Silva, Andrea Rivera-Cavazos, Devany Paola Morales-Rodriguez, Mauricio Hurtado-Cabrera, Ricardo Kalife-Assad, Diana Villarreal-Parra, Alejandro Loose-Esparza, Juan José Gutiérrez-Arias and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Bridging Gaps in Long COVID Therapy: A Review.Current medicinal chemistry · 2026
    Review
  4. Article
  5. Article
  6. HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record-Based Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Maria Elena Romero-IbarguengoitiaResearch Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, México. MROMEROI@novaservicios.com.mx.
Juan Francisco Rodríguez-TorresEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Arnulfo Garza-SilvaResearch Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, México.
Andrea Rivera-CavazosResearch Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, México.
Devany Paola Morales-RodriguezResearch Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, México.
Mauricio Hurtado-CabreraEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Ricardo Kalife-AssadEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Diana Villarreal-ParraEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Alejandro Loose-EsparzaEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Juan José Gutiérrez-AriasEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Yaressi Guadalupe Mata-PorrasEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Daniela Abigail Ojeda-SalazarEscuela de Medicina, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Miguel Angel Sanz-SánchezResearch Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, México.
Arnulfo González-CantúResearch Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, México.
Elena AzzoliniIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
Maria RescignoIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
University of Monterrey · MXHumanitas University · ITIRCCS Humanitas Research Hospital · ITUniversidad Autónoma de Nuevo León · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic had a profound global impact, characterized by a high fatality rate and the emergence of enduring consequences known as Long COVID. Our study sought to determine the prevalence of Long COVID syndrome within a population of Northeastern Mexico, correlating it with patients' comorbidities, number of COVID-19 reinfection, and vaccination status. Employing an observational cross-sectional approach, we administered a comprehensive questionnaire covering medical history, demographics, vaccination status, COVID-related symptoms, and treatment. Our participant cohort included 807 patients, with an average age of 41.5 (SD 13.6) years, and women accounting 59.3% of the cohort. The follow-up was 488 (IQR 456) days. One hundred sixty-eight subjects (20.9%) met Long COVID criteria. Long COVID-19 was more prevalent when subjects had reinfections (p = 0.02) and less frequent when they had a complete vaccination scheme (p = 0.05). Through logistic regression, we found that male gender (OR 0.5, p ≤ 0.001), blood types of AB- (OR 0.48, p = 0.003) and O- (OR 0.27, p ≤ 0.001) in comparison with A+ and two doses of vaccines (OR 0.5, p = 006) to be protective factors against Long COVID; while higher BMI (OR 1.04, p = 0.005) was a risk factor. We saw that the prevalence of Long COVID was different within vaccinated patients and specific blood types, while being female and a higher BMI were associated with an increased risk of having long-COVID.

Indexed as

COVID-19Post-Acute COVID-19 SyndromeAdultFemaleHumansMalePandemicsReinfectionRisk FactorsVaccination

Identifiers

PMID38307886
PMCPMC10837423
OpenAlexW4391466001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.